B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.
B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.